{"protocolSection": {"identificationModule": {"nctId": "NCT03620747", "orgStudyIdInfo": {"id": "LPS15023"}, "secondaryIdInfos": [{"id": "2017-002134-23", "type": "EUDRACT_NUMBER"}, {"id": "U1111-1196-5369", "type": "OTHER", "domain": "UTN"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)", "officialTitle": "Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial"}, "statusModule": {"statusVerifiedDate": "2023-02", "overallStatus": "COMPLETED", "startDateStruct": {"date": "2018-08-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-02-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-02-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-07-26", "studyFirstSubmitQcDate": "2018-08-06", "studyFirstPostDateStruct": {"date": "2018-08-08", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-02-17", "resultsFirstSubmitQcDate": "2023-02-17", "resultsFirstPostDateStruct": {"date": "2023-03-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-17", "lastUpdatePostDateStruct": {"date": "2023-03-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}, "collaborators": [{"name": "Regeneron Pharmaceuticals", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Primary Objective:\n\nTo describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).", "detailedDescription": "Duration per participant was until dupilumab approval for use in asthma and market availability to the participant, or a maximum of 144 weeks (i.e., about 3 years) after the start of treatment (Visit 1), whichever came first."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 393, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dupilumab", "type": "EXPERIMENTAL", "description": "Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to (\\>=) 6 weeks after study LTS12551 (NCT02134028), received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid \\[OCS\\] for those participants from the original parent study EFC13691 \\[NCT02528214\\]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.", "interventionNames": ["Drug: Dupilumab SAR231893 (REGN668)"]}], "interventions": [{"type": "DRUG", "name": "Dupilumab SAR231893 (REGN668)", "description": "Pharmaceutical form: prefilled syringes\n\nRoute of administration: subcutaneous", "armGroupLabels": ["Dupilumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)", "description": "An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product \\[IMP\\] up to 12 weeks after the last dose of the IMP).", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)"}, {"measure": "Treatment-emergent Adverse Event Rate (Event Per 100 Participant-years)", "description": "An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the IMP up to 12 weeks after last dose of the IMP). TEAE event rate was defined as the number of TEAE events per 100 participant-years.", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)"}], "secondaryOutcomes": [{"measure": "Adverse Events of Special Interest (AESIs) Event Rate (Event Per100 Participant-years)", "description": "An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. AESIs were AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AESI event rate was defined as the number of AESI events per 100 participant-years.", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)"}, {"measure": "Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Discontinuation", "description": "AE: any untoward medical occurrence in participants that received IMP and did not necessarily had to have causal relationship with treatment. TEAEs: AEs developed/worsened in grade/become serious during the TEAE period (from first dose of IMP up to 12 weeks after last dose of IMP).SAE: any untoward medical occurrence at any dose resulted in death, was life-threatening, required inpatient hospitalization, prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. AESI: AE (serious/non-serious) of scientific and medical concern specific to Sponsor's product/program, for which ongoing monitoring and immediate notification by Investigator to Sponsor required.", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Participants with asthma who completed the treatment period in the previous dupilumab asthma clinical study LTS12551.\n* Signed written informed consent.\n\nExclusion criteria:\n\n* Participants who experienced any systemic hypersensitivity reactions to the investigational medicinal product in the previous dupilumab asthma study LTS12551, which, in the opinion of the Investigator, could indicate that continued treatment with dupilumab might present an unreasonable risk for the participant.\n* Clinically significant comorbidity/lung disease other than asthma.\n* Participants with active autoimmune disease or participants who, as per Investigator's medical judgment, were suspected of having high risk for developing autoimmune disease.\n* History of malignancy within 5 years before enrollment except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site Number :840099", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Investigational Site Number :840087", "city": "Scottsdale", "state": "Arizona", "zip": "85248", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Investigational Site Number :840402", "city": "Tucson", "state": "Arizona", "zip": "85721", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Investigational Site Number :840132", "city": "Little Rock", "state": "Arkansas", "zip": "72209", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Investigational Site Number :840121", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Investigational Site Number :840403", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number :840130", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number :840115", "city": "Ocoee", "state": "Florida", "zip": "34761", "country": "United States", "geoPoint": {"lat": 28.56917, "lon": -81.54396}}, {"facility": "Investigational Site Number :840055", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Investigational Site Number :840079", "city": "Twin Falls", "state": "Idaho", "zip": "83301", "country": "United States", "geoPoint": {"lat": 42.56297, "lon": -114.46087}}, {"facility": "Investigational Site Number :840032", "city": "Fort Mitchell", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Investigational Site Number :840064", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Investigational Site Number :840052", "city": "Chevy Chase", "state": "Maryland", "zip": "20815", "country": "United States", "geoPoint": {"lat": 39.00287, "lon": -77.07115}}, {"facility": "Investigational Site Number :840073", "city": "Gaithersburg", "state": "Maryland", "zip": "20878", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Investigational Site Number :840018", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Investigational Site Number :840102", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number :840004", "city": "Papillion", "state": "Nebraska", "zip": "27103", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Investigational Site Number :840068", "city": "West Long Branch", "state": "New Jersey", "zip": "07764", "country": "United States", "geoPoint": {"lat": 40.29039, "lon": -74.01764}}, {"facility": "Investigational Site Number :840126", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Investigational Site Number :840907", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Investigational Site Number :840942", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Investigational Site Number :840067", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Investigational Site Number :840091", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number :840070", "city": "Allen", "state": "Texas", "zip": "75013", "country": "United States", "geoPoint": {"lat": 33.10317, "lon": -96.67055}}, {"facility": "Investigational Site Number :840062", "city": "Amarillo", "state": "Texas", "zip": "79109", "country": "United States", "geoPoint": {"lat": 35.222, "lon": -101.8313}}, {"facility": "Investigational Site Number :840124", "city": "Cypress", "state": "Texas", "zip": "77429", "country": "United States", "geoPoint": {"lat": 29.96911, "lon": -95.69717}}, {"facility": "Investigational Site Number :840023", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number :840922", "city": "Fort Worth", "state": "Texas", "zip": "76109", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number :840027", "city": "Fort Worth", "state": "Texas", "zip": "76244", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number :840008", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Investigational Site Number :840035", "city": "Draper", "state": "Utah", "zip": "84020", "country": "United States", "geoPoint": {"lat": 40.52467, "lon": -111.86382}}, {"facility": "Investigational Site Number :840077", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Investigational Site Number :840057", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "Investigational Site Number :840059", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Investigational Site Number :840951", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"facility": "Investigational Site Number :032096", "city": "Bahia Blanca", "state": "Buenos Aires", "zip": "B8000JRB", "country": "Argentina", "geoPoint": {"lat": -38.71959, "lon": -62.27243}}, {"facility": "Investigational Site Number :032091", "city": "Capital Federal", "state": "Buenos Aires", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number :032002", "city": "La Plata", "state": "Buenos Aires", "zip": "B1900BNN", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Investigational Site Number :032006", "city": "Rosario", "state": "Santa Fe", "zip": "S2000BRH", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Investigational Site Number :032005", "city": "Rosario", "state": "Santa Fe", "zip": "S2000JKR", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Investigational Site Number :032004", "city": "Buenos Aires", "zip": "2317", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number :032003", "city": "Ciudad Autonoma Bs As", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number :032097", "city": "Ciudad Autonoma Buenos Aires", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number :032010", "city": "Ciudad Autonoma Buenos Aires", "zip": "C1414CGA", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number :032001", "city": "Ciudad Autonoma Buenos Aires", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number :032012", "city": "San Miguel de Tucuman", "zip": "T4000CHE", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Investigational Site Number :032009", "city": "San Miguel De Tucum\u00c3\u00a1n", "zip": "4000", "country": "Argentina"}, {"facility": "Investigational Site Number :056003", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Investigational Site Number :124006", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number :124017", "city": "Vancouver", "state": "British Columbia", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number :124016", "city": "Hamilton", "state": "Ontario", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Investigational Site Number :124013", "city": "Ottawa", "state": "Ontario", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Investigational Site Number :124002", "city": "Toronto", "state": "Ontario", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number :124001", "city": "Montreal", "state": "Quebec", "zip": "H2X 1P1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number :124012", "city": "Montreal", "state": "Quebec", "zip": "H3G 1A4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number :124010", "city": "Montr\u00c3\u00a9al", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada"}, {"facility": "Investigational Site Number :124014", "city": "Qu\u00c3\u00a9bec", "state": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Investigational Site Number :124007", "city": "Trois-Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Investigational Site Number :124018", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Investigational Site Number :250009", "city": "Brest cedex 2", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Investigational Site Number :250010", "city": "Lille Cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Investigational Site Number :250006", "city": "Lyon cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Investigational Site Number :250001", "city": "Marseille", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Investigational Site Number :250002", "city": "Montpellier cedex 5", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Investigational Site Number :250005", "city": "Nantes cedex", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Investigational Site Number :250008", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Investigational Site Number :276006", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigational Site Number :276010", "city": "Frankfurt am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Investigational Site Number :276011", "city": "Grosshansdorf", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Investigational Site Number :276009", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Investigational Site Number :276005", "city": "Ruedersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Investigational Site Number :376001", "city": "Kfar- Sava", "zip": "4428164", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Investigational Site Number :376005", "city": "Petach-Tikva", "zip": "4941492", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Investigational Site Number :376002", "city": "Rehovot", "zip": "76100", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Investigational Site Number :392106", "city": "Mizunami-shi", "state": "Gifu", "zip": "509-6134", "country": "Japan", "geoPoint": {"lat": 35.36667, "lon": 137.25}}, {"facility": "Investigational Site Number :392043", "city": "Ota-shi", "state": "Gunma", "zip": "373-0807", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number :392021", "city": "Fukuyama-shi", "state": "Hiroshima", "zip": "720-0001", "country": "Japan", "geoPoint": {"lat": 34.48333, "lon": 133.36667}}, {"facility": "Investigational Site Number :392108", "city": "Hiroshima-shi", "state": "Hiroshima", "zip": "734-8530", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Investigational Site Number :392164", "city": "Muroran-shi", "state": "Hokkaido", "zip": "0143-0076", "country": "Japan", "geoPoint": {"lat": 42.31722, "lon": 140.98806}}, {"facility": "Investigational Site Number :392008", "city": "Sapporo-shi", "state": "Hokkaido", "zip": "062-8618", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Investigational Site Number :392034", "city": "Sapporo-shi", "state": "Hokkaido", "zip": "064-0804", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Investigational Site Number :392006", "city": "Tomakomai-shi", "state": "Hokkaido", "zip": "053-8506", "country": "Japan", "geoPoint": {"lat": 42.63694, "lon": 141.60333}}, {"facility": "Investigational Site Number :392162", "city": "Kobe-shi", "state": "Hyogo", "zip": "650-0017", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Investigational Site Number :392020", "city": "Naka-gun", "state": "Ibaraki", "zip": "319-1113", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "Investigational Site Number :392011", "city": "Sakaide-shi", "state": "Kagawa", "zip": "762-8550", "country": "Japan"}, {"facility": "Investigational Site Number :392014", "city": "Yokohama-shi", "state": "Kanagawa", "zip": "231-8682", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Investigational Site Number :392153", "city": "Kyoto-shi", "state": "Kyoto", "zip": "615-8087", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number :392170", "city": "Osaki-shi", "state": "Miyagi", "zip": "989-6183", "country": "Japan"}, {"facility": "Investigational Site Number :392045", "city": "Uruma-shi", "state": "Okinawa", "zip": "904-2293", "country": "Japan", "geoPoint": {"lat": 26.37609, "lon": 127.85908}}, {"facility": "Investigational Site Number :392119", "city": "Kishiwada-shi", "state": "Osaka", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Investigational Site Number :392005", "city": "Naruto-shi", "state": "Tokushima", "zip": "772-0017", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.41667}}, {"facility": "Investigational Site Number :392002", "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0028", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number :392112", "city": "Chuo-ku", "state": "Tokyo", "zip": "104-0031", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number :392133", "city": "Machida-shi", "state": "Tokyo", "zip": "194-0023", "country": "Japan", "geoPoint": {"lat": 35.54028, "lon": 139.45083}}, {"facility": "Investigational Site Number :392177", "city": "Ome-shi", "state": "Tokyo", "zip": "198-0042", "country": "Japan", "geoPoint": {"lat": 35.78389, "lon": 139.24306}}, {"facility": "Investigational Site Number :392038", "city": "Setagaya-ku", "state": "Tokyo", "zip": "158-0097", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Investigational Site Number :392167", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "142-8666", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Investigational Site Number :392173", "city": "Tachikawa-shi", "state": "Tokyo", "zip": "190-0012", "country": "Japan"}, {"facility": "Investigational Site Number :392185", "city": "Akashi-shi", "zip": "674-0063", "country": "Japan", "geoPoint": {"lat": 34.65522, "lon": 135.00687}}, {"facility": "Investigational Site Number :392007", "city": "Chuo-Ku", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number :392012", "city": "Edogawa-ku", "zip": "134-0083", "country": "Japan"}, {"facility": "Investigational Site Number :392030", "city": "Habikino-shi", "zip": "583-8588", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Investigational Site Number :392004", "city": "Himeji-shi", "zip": "672-8064", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Investigational Site Number :392158", "city": "Hiroshima-shi", "zip": "732-0052", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Investigational Site Number :392013", "city": "Iizuka-shi", "zip": "820-8505", "country": "Japan", "geoPoint": {"lat": 33.63654, "lon": 130.68678}}, {"facility": "Investigational Site Number :392042", "city": "Isesaki-shi", "zip": "372-0831", "country": "Japan", "geoPoint": {"lat": 36.31667, "lon": 139.2}}, {"facility": "Investigational Site Number :392142", "city": "Kasuga-shi", "zip": "816-0813", "country": "Japan"}, {"facility": "Investigational Site Number :392040", "city": "Kodaira-shi", "zip": "187-0024", "country": "Japan"}, {"facility": "Investigational Site Number :392044", "city": "Kokubunji-shi", "zip": "185-0014", "country": "Japan", "geoPoint": {"lat": 35.70222, "lon": 139.47556}}, {"facility": "Investigational Site Number :392010", "city": "Kurashiki-shi", "zip": "712-8064", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Investigational Site Number :392036", "city": "Kyoto-shi", "zip": "612-0026", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number :392144", "city": "Minato-ku", "zip": "105-0003", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number :392122", "city": "Minato-ku", "zip": "108-8606", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number :392163", "city": "Nagoya-shi", "zip": "454-8509", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "Investigational Site Number :392155", "city": "Osakasayama-shi", "zip": "589-0022", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigational Site Number :392152", "city": "Osakasayama-shi", "zip": "589-8511", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigational Site Number :392127", "city": "Ota-ku", "zip": "145-0071", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number :392169", "city": "Sagamihara-shi", "zip": "252-0392", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Investigational Site Number :392130", "city": "Shinjuku-ku", "zip": "162-8655", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Investigational Site Number :392165", "city": "Sumida-ku", "zip": "130-8587", "country": "Japan"}, {"facility": "Investigational Site Number :392146", "city": "Tachikawa-shi", "zip": "190-0014", "country": "Japan"}, {"facility": "Investigational Site Number :392029", "city": "Tsu-shi", "zip": "514-0125", "country": "Japan", "geoPoint": {"lat": 34.73333, "lon": 136.51667}}, {"facility": "Investigational Site Number :392168", "city": "Uozu-shi", "zip": "937-0042", "country": "Japan", "geoPoint": {"lat": 36.8, "lon": 137.4}}, {"facility": "Investigational Site Number :392132", "city": "Urasoe-shi", "zip": "901-2121", "country": "Japan", "geoPoint": {"lat": 26.25902, "lon": 127.73012}}, {"facility": "Investigational Site Number :528001", "city": "Arnhem", "zip": "6815 AD", "country": "Netherlands", "geoPoint": {"lat": 51.98, "lon": 5.91111}}, {"facility": "Investigational Site Number :710009", "city": "Brandfort", "zip": "9400", "country": "South Africa", "geoPoint": {"lat": -28.70008, "lon": 26.45968}}, {"facility": "Investigational Site Number :710011", "city": "Cape Town", "zip": "7505", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number :710001", "city": "Cape Town", "zip": "7531", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number :710091", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number :710092", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number :710006", "city": "Durban", "zip": "4071", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Investigational Site Number :710007", "city": "Pretoria", "zip": "0087", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with moderate to severe asthma who had completed the parent study TRAVERSE-LTS12551 (NCT02134028) were enrolled in this current study (LPS15023).", "recruitmentDetails": "The study was conducted at 138 sites in 10 countries. A total of 393 participants were enrolled in the study between 30 August 2018 and 27 August 2020.", "groups": [{"id": "FG000", "title": "Dupilumab", "description": "Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to \\[\\>=\\] 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid \\[OCS\\] for those participants from the original parent study EFC13691 \\[NCT02528214\\]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "393"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "374"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}]}], "dropWithdraws": [{"type": "Participant decision", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Poor compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Other-unspecified", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Analysis was performed on all enrolled participants.", "groups": [{"id": "BG000", "title": "Dupilumab", "description": "Participants received SC dose of dupilumab 300 mg q2w from Week 0 up to Week 132. Participants who discontinued treatment for \\>= 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose ICS as maintained in study LTS12551 in combination with controllers (and/or OCS for those participants from the original parent study EFC13691). Salbutamol/albuterol hydrofluoroalkane pressurized MDI or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "393"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "393"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "52.1", "spread": "14.19"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "393"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "231"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "162"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)", "description": "An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product \\[IMP\\] up to 12 weeks after the last dose of the IMP).", "populationDescription": "Analysis was performed on safety population that included all participants who had actually received at least one dose or part of a dose of IMP.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)", "groups": [{"id": "OG000", "title": "Dupilumab", "description": "Participants received SC dose of dupilumab 300 mg q2w from Week 0 up to Week 132. Participants who discontinued treatment for \\>= 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose ICS as maintained in study LTS12551 in combination with controllers (and/or OCS for those participants from the original parent study EFC13691). Salbutamol/albuterol hydrofluoroalkane pressurized MDI or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "393"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.5", "lowerLimit": "47.40", "upperLimit": "62.26"}]}]}]}, {"type": "PRIMARY", "title": "Treatment-emergent Adverse Event Rate (Event Per 100 Participant-years)", "description": "An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the IMP up to 12 weeks after last dose of the IMP). TEAE event rate was defined as the number of TEAE events per 100 participant-years.", "populationDescription": "Analysis was performed on safety population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per 100 participant-years", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)", "groups": [{"id": "OG000", "title": "Dupilumab", "description": "Participants received SC dose of dupilumab 300 mg q2w from Week 0 up to Week 132. Participants who discontinued treatment for \\>= 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose ICS as maintained in study LTS12551 in combination with controllers (and/or OCS for those participants from the original parent study EFC13691). Salbutamol/albuterol hydrofluoroalkane pressurized MDI or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "393"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "171.4", "lowerLimit": "162.71", "upperLimit": "180.43"}]}]}]}, {"type": "SECONDARY", "title": "Adverse Events of Special Interest (AESIs) Event Rate (Event Per100 Participant-years)", "description": "An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. AESIs were AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AESI event rate was defined as the number of AESI events per 100 participant-years.", "populationDescription": "Analysis was performed on safety population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events per 100 participant-years", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)", "groups": [{"id": "OG000", "title": "Dupilumab", "description": "Participants received SC dose of dupilumab 300 mg q2w from Week 0 up to Week 132. Participants who discontinued treatment for \\>= 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose ICS as maintained in study LTS12551 in combination with controllers (and/or OCS for those participants from the original parent study EFC13691). Salbutamol/albuterol hydrofluoroalkane pressurized MDI or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "393"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.0", "lowerLimit": "4.40", "upperLimit": "7.99"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Discontinuation", "description": "AE: any untoward medical occurrence in participants that received IMP and did not necessarily had to have causal relationship with treatment. TEAEs: AEs developed/worsened in grade/become serious during the TEAE period (from first dose of IMP up to 12 weeks after last dose of IMP).SAE: any untoward medical occurrence at any dose resulted in death, was life-threatening, required inpatient hospitalization, prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. AESI: AE (serious/non-serious) of scientific and medical concern specific to Sponsor's product/program, for which ongoing monitoring and immediate notification by Investigator to Sponsor required.", "populationDescription": "Analysis was performed on safety population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)", "groups": [{"id": "OG000", "title": "Dupilumab", "description": "Participants received SC dose of dupilumab 300 mg q2w from Week 0 up to Week 132. Participants who discontinued treatment for \\>= 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose ICS as maintained in study LTS12551 in combination with controllers (and/or OCS for those participants from the original parent study EFC13691). Salbutamol/albuterol hydrofluoroalkane pressurized MDI or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "393"}]}], "classes": [{"title": "TESAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.6"}]}]}, {"title": "AESIs", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.1"}]}]}, {"title": "AEs leading to study discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)", "description": "Reported AEs and deaths were TEAEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the IMP up to 12 weeks after last dose of the IMP). Analysis was performed on safety population.", "eventGroups": [{"id": "EG000", "title": "Dupilumab", "description": "Participants received SC dose of dupilumab 300 mg q2w from Week 0 up to Week 132. Participants who discontinued treatment for \\>= 6 weeks after study LTS12551, received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose ICS as maintained in study LTS12551 in combination with controllers (and/or OCS for those participants from the original parent study EFC13691). Salbutamol/albuterol hydrofluoroalkane pressurized MDI or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.", "deathsNumAffected": 5, "deathsNumAtRisk": 393, "seriousNumAffected": 22, "seriousNumAtRisk": 393, "otherNumAffected": 93, "otherNumAtRisk": 393}], "seriousEvents": [{"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Pudendal canal syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 393}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Tracheal stenosis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Enterovesical fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 393}]}, {"term": "COVID-19 pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 393}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 393}]}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 77, "numAffected": 52, "numAtRisk": 393}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 22, "numAtRisk": 393}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 36, "numAffected": 33, "numAtRisk": 393}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi aventis recherche & d\u00e9veloppement", "email": "Contact-US@sanofi.com", "phone": "800-633-1610", "phoneExt": "6#"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-02-27", "uploadDate": "2023-02-15T11:08", "filename": "Prot_000.pdf", "size": 1051022}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2021-03-15", "uploadDate": "2023-02-15T11:10", "filename": "SAP_001.pdf", "size": 1516911}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}